Global Lymph Cancer Testing Market - 2020-2027
|出版日期||內容資訊||英文 180 Pages
|全球惡性淋巴腫瘤檢驗市場(2020年∼2027年) Global Lymph Cancer Testing Market - 2020-2027|
|出版日期: 2021年05月10日||內容資訊: 英文 180 Pages||
惡性淋巴瘤是起源於淋巴結、脾臟、胸腺和骨髓等淋巴組織的惡性腫瘤。儘管惡性淋巴瘤可發生於任何年齡，但它是 15 至 24 歲兒童和年輕人中最常見的癌症之一。惡性淋巴瘤分為非霍奇金淋巴瘤，約佔總數的90%，霍奇金淋巴瘤，活檢具有特徵性表現。惡性淋巴瘤的治療包括化學療法、免疫療法、放射療法、骨髓移植或其組合。
The global lymph cancer testing market size was valued US$ XX billion in 2019 and is estimated to reach US$ XX billion by 2027, growing at a CAGR of XX % during the forecast period (2020-2027).
Lymph cancer is a type of cancer of the lymphatic system, which is part of the body's germ-fighting network, including the lymph nodes, spleen, thymus gland and bone marrow. It can affect all those areas and spread to other organs like bone marrow, lungs, liver of the body. Lymph cancer occurs in people of any age, but it is among the most common causes trusted Source of cancer in children and young adults aged 15-24 years. It is often treatable. There are mainly two types of lymphoma, which spread and are treated differently Non-Hodgkin lymphoma (which accounts for about 90% of lymphomas) and Hodgkin lymphoma (which has a characteristic appearance in biopsies). Lymph cancer treatment may involve chemotherapy, immunotherapy medications, radiation therapy, a bone marrow transplant or some combination.
The global Lymph Cancer Testing market growth is driven by the growing incidence of lymph cancer cases, increasing demand for preventive medicines and companion diagnostics, and favorable government initiatives are among the key factors driving the market growth.
Growing incidence of lymph cancer cases, is expected to drive the market growth
As per the American cancer society, in 2020, there are expected to be 85,720 new cases of lymphoma diagnosed in the US (8,480 cases of HL, 77,240 cases of NHL). An estimated 791,550 people are living with, or in remission from, lymphoma in the US. About 146,789 people live with or in remission from Hodgkin lymphoma, and 644,761 people live with or in remission from non-Hodgkin lymphoma. In 2020, the number of cases expected to be diagnosed in children and adolescents younger than 15 years was 332 for HL and 553 for NHL.
High cost associated diagnostic tests is likely to hamper the market growth
According to the data presented in National Library of medicine, the cost to identify a single positive sentinel lymph node (SLN) was $47,906. This may restrict the market growth.
COVID-19 Impact Analysis
Due to the covid-19 pandemic outbreak, the market for Global Next Generation Cancer Diagnostic Devices Market was seen to be down, due to the barriers in production and sales segments. Since the outbreak led to the shutdown of all manufacturing firms except for masks, sanitizers and ventilators. Hence, the Diagnostic devices were manufactured less compared to previous years, during the outbreak.
Based on the test type, the global lymph cancer testing market segmented into Blood Tests, Sentinel lymph node Biopsy, CT Scan & PET Scan and Others
Sentinel lymph node Biopsy segment is expected to grow at the fastest CAGR during the forecast period (2020-2027)
The sentinel lymph node biopsy (SLNB) test is a type of biopsy procedure in which the sentinel lymph node is detected, removed, and examined to determine whether cancer cells are present or not. Negative SLNB results suggest that cancer has not yet spread to nearby lymph nodes or other body organs. In contrast, positive SLNB results indicate that cancer is present in the node and that it may have spread to other nearby lymph nodes (called regional lymph nodes) and, possibly, other body organs. First, the sentinel lymph node must be located. For this to do, the surgeon injects a radioactive substance, a blue dye, or both near the tumor and then uses a device to detect lymph nodes containing the radioactive substance or looks for lymph nodes stained with the blue dye. Once the node is located, the surgeon makes a small incision (about 1/2 inch) in the overlying skin and removes them and then the sentinel node is then checked for the presence of cancer cells by a pathologist. For instance, Novadaq Technologies ULC, now a part of Stryker conducting Phase 3 Study to Assess the Safety and Effectiveness of IC2000 and SPY Fluorescence Imaging Systems in the Visualization of Lymphatic Vessels and Lymph Nodes During Lymphatic Mapping and Sentinel Lymph Node Biopsy.
Based on End user, the global Lymph Cancer Testing market is segmented into Hospitals, Diagnostic and imaging centers, Clinics and Others.
As an end-user, hospitals held the largest market share during the historical period (2014-2019), and the situation in the coming years is projected to be the same. This is because hospitals serve a far larger number of patients relative to diagnostic centers and clinics and developing healthcare infrastructure in emerging nations.
North America expected to hold a major market share in the global lymph cancer testing market due to the rising prevalence of lymph cancer in the U.S. is likely to boost testing devices demand. Cancer is the second-leading cause of death in the United States. As per the American cancer society, In 2020, approximately 89,500 cancer cases were diagnosed, and around 9,300 cancer deaths in adolescents and young adults (AYAs) aged 15 to 39 years in the U.S. In 2020, there are expected to be 85,720 new cases of lymphoma diagnosed in the US (8,480 cases of HL, 77,240 cases of NHL). Moreover, the U.S. is considered the largest market for medical devices globally, which invariably makes it a lucrative pocket for cancer diagnostics. According to SelectUSA, the U.S. medical devices market accounted for 40% of the global market in 2017. By 2023, it is expected to reach US$ 203 billion in valuation.
Favorable healthcare policies, high per capita healthcare spending, high healthcare infrastructure created the adoption of advanced cancer diagnostic technologies such as imaging in the U.S. Also, significant players' presence is supporting growth in the U.S. Strategies undertaken by these companies include product launches and mergers, expansion plans, which will continue aiding overall expansion in the U.S.
The Asia-Pacific region is expected to be the fastest-growing region in the global neurodiagnostic Direct marketing initiatives by the manufacturers to consumers. It plays a crucial role in increasing the target audience and raising the market size in this region. Also, novel product launches by key players are contributing to the growth of the market. For instance, in March 2017, Hitachi, Ltd. (Japan), launched ECHELON Smart, a 1.5T superconductive MRI system.
The global lymph cancer testing market is quite competitive with some key competitors like GE Healthcare, Siemens Healthineer, Abbott laboratories, Canon Medical Systems, Agilent Technologies, MDx Health, Beckman Coulter, Myriad Genetics, Ambry Genetics, Bio Rad Laboratories. The growth of these companies is attributed to product launch, acquisition of independent companies and investments in multiple sectors. For instance, researchers at the Naval Medical Center San Diego and Google's AI research division Google AI, developed a reliable solution comprised of cancer-detecting algorithms used for autonomous evaluation of lymph node biopsies.
Company Overview: GE Healthcare is an American multinational conglomerate based in Chicago, Illinois and incorporated in New York. The company has been a manufacturer and distributor of diagnostic imaging agents and radio pharmaceuticals used in medical imaging procedures for imaging modalities since 2017.
Product Portfolio: The Company's portfolio comprised of diagnostic imaging agents.
GE Healthcare (US) unveiled its SIGNA Premier 3.0T magnetic resonance imaging (MRI) device in Canada in March 2018.
The global lymph cancer testing market report would provide an access to an approx. market data 61table, 54 figures and 300 pages.
LIST NOT EXHAUSTIVE